cemiplimab

Phase 3

Regeneron Pharmaceuticals, Inc. (REGN)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

REGNPhase 2$57.3B

Cemiplimab Phase 2 Est. Readout

cemiplimab• Advanced Cutaneous Squamous Cell Carcinoma15

Q3 2027~QConfirmed

CT.gov

00%

Q2 '27

REGNPhase 2$57.3B

Cemiplimab Phase 2 Est. Readout

cemiplimab• Advanced Cutaneous Squamous Cell Carcinoma32

Q2 2027~QConfirmed

CT.gov

00%

Q2 '27

REGNPhase 2$57.3B

Cemiplimab Phase 2 Est. Readout

cemiplimab• Advanced Cutaneous Squamous Cell Carcinoma50

Q2 2027~QConfirmed

CT.gov

00%

Q1 '27

REGNPhase 3$57.3B

cemiplimab Phase 3 Est. Readout

cemiplimab• Advanced Cutaneous Squamous Cell Carcinoma560

Q1 2027~QConfirmed

CT.gov

00%

Nov '26

REGNPhase 3$57.3B

Cemiplimab Phase 3 Est. Readout

cemiplimab• Advanced Cutaneous Squamous Cell Carcinoma415

Nov 2026~ConfirmedSTALE

CT.gov

00%

Development History

Aug '26

REGNPhase 2$57.3B

Cemiplimab Phase 2 Est. Readout

cemiplimab• Advanced Cutaneous Squamous Cell Carcinoma195

Aug 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Advanced Cutaneous Squamous Cell Carcinoma

View Full Landscape

Drug Information

Target Indication

Advanced Cutaneous Squamous Cell Carcinoma

Clinical Trial

NCT02760498

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

REGN

Regeneron Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

AlirocumabPhase 3

Homozygous Familial Hypercholesterolemia

StatinPhase 3

Hypercholesterolemia

Intravitreal Aflibercept Injection (IAI)Phase 3

Neovascular Age-Related Macular Degeneration

LibtayoPhase 3

Non-Small Cell Lung Cancer

REGN5715Phase 3

Allergic Conjunctivitis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts